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■ Abstract
Background: The pathophysiology and triggers of idiopathic nonhistaminergic angioedema are unclear. This study aimed to assess 
autoreactivity in recurrent idiopathic angioedema associated or not with wheals. 
Methods: The study population comprised 19 patients with recurrent idiopathic nonhistaminergic angioedema without wheals, 38 patients with 
angioedema and chronic urticaria (CU), and 52 patients with CU without angioedema. Twenty healthy individuals served as controls. Autoreactivity 
was evaluated in vivo using the autologous serum skin test (ASST) and in vitro by measuring serum-induced basophil histamine release (BHR).
Results: ASST results were negative in all patients with idiopathic angioedema without wheals and in healthy controls and positive in 29 of the 
38 patients with angioedema and CU (76.3%) and in 26 of the 52 patients with CU without angioedema (50%) (P<.0001 for both CU groups). 
BHR was negative in the healthy controls and positive in 2 of the 19 patients with idiopathic angioedema without wheals (10.5%), in 18 of 
the 38 patients with angioedema and CU (47.3%) (P<.0001), and in 11 of the 52 patients with CU without angioedema (21.1%) (P<.03). 
Conclusion: The different rates of autoreactivity observed in patients with idiopathic nonhistaminergic angioedema without wheals and in 
patients with CU either with or without angioedema suggest that these disorders have a different pathophysiology. The failure to detect 
circulating vasoactive factors and histamine-releasing autoantibodies explains why H1 antihistamines are scarcely effective in most patients 
with idiopathic angioedema without wheals. However, they represent the cornerstone of CU treatment.
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■ Resumen
Antecedentes: Se desconocen la fi siopatología y los desencadenantes del angioedema idiopático no histaminérgico. El objetivo de este 
estudio fue evaluar la autorreactividad en el angioedema idiopático recurrente asociado o no a la presencia de habones. 
Métodos: La población en estudio incluyó a 19 pacientes con angioedema idiopático no histaminérgico recurrente sin presencia de habones, 
a 38 pacientes con angioedema y urticaria crónica (UC), y a 52 pacientes con UC sin angioedema. Veinte individuos sanos sirvieron como 
controles. Se evaluó la autorreactividad in vivo mediante la prueba cutánea con suero autólogo (PCSA) e in vitro mediante la determinación 
de la liberación de histamina de basófi los (LHB) inducida por suero.
Resultados: Los resultados de la PCSA fueron negativos en todos los pacientes con angioedema idiopático sin presencia de habones y en los 
controles sanos, y positivos en 29 de los 38 pacientes con angioedema y UC (76,3%) y en 26 de los 52 pacientes con CU sin angioedema 
(50%) (p < 0,0001 para ambos grupos con UC). Los resultados de la LHB fueron negativos en los controles sanos y positivos en 2 de los 
19 pacientes con angioedema idiopático sin presencia de habones (10,5%), en 18 de los 38 pacientes con angioedema y UC (47,3%)    
(p < 0,0001), y en 11 de los 52 pacientes con UC sin angioedema (21,1%) (p < 0,03). 
Conclusión: Los diferentes índices de autorreactividad que se observaron en pacientes con angioedema idiopático no histaminérgico sin 
presencia de habones y en pacientes con UC con o sin angioedema permiten suponer que estos trastornos tienen una fi siopatología 
distinta. El hecho de que no se detectaran factores vasoactivos circulantes y autoanticuerpos liberadores de histamina explica por qué 
los antihistamínicos H1 resultan apenas efi caces en la mayoría de pacientes con angioedema idiopático sin presencia de habones y, sin 
embargo, representan la piedra angular del tratamiento de la UC.
Palabras clave: Prueba cutánea con suero autólogo; autorreactividad; liberación de histamina de basófi los; angioedema idiopático; 
urticaria crónica.  
Autoreactivity in Idiopathic Angioedema and Urticaria
 J Investig Allergol Clin Immunol 2012; Vol. 22(2): 87-91© 2012 Esmon Publicidad
88
Introduction
Angioedema is a self-limiting localized swelling that 
involves subcutaneous and submucosal tissues and is 
generally not associated with changes in skin color, burning 
sensation, or itchiness. It is thought to result from a local 
increase in the permeability of subcutaneous and submucosal 
capillaries and postcapillary venules in response to mediators 
such as histamine and bradykinin [1,2]. In most patients, 
angioedema occurs with wheals, is largely histaminergic, 
and responds to antiallergic drugs such as H1 antihistamines 
and corticosteroids [3-5]. The most common form is allergic 
angioedema, which is generally due to allergy to food, drugs, 
and insect venom [3]. Immunoglobulin (Ig) E–mediated 
mast cell degranulation with subsequent histamine release is 
considered to underlie the disorder in most cases. However, 
the pathophysiology of recurrent angioedema with urticaria 
may also be linked to an autoimmune process leading to 
mast cell degranulation. Chronic spontaneous urticaria (CU), 
which is associated with angioedema in about 30% of cases, 
is now recognized as an autoimmune disease associated with 
histamine-releasing autoantibodies in a consistent proportion 
of patients [6]. Substantial advances in our understanding of 
the pathogenesis of this disease have been made during the 
last 2 decades, following the observation by Grattan et al [7] 
that intradermal injection of autologous serum (autologous 
serum skin test [ASST]) caused a wheal-and-fl are reaction 
in about 50% of CU patients. The main factors inducing skin 
reactivity to autologous serum were subsequently identifi ed 
as autoantibodies directed against the α subunit of the high 
affi nity IgE receptor (FcεRI) or against IgE [8,9]. These 
fi ndings led to the interpretation of CU as an autoimmune 
disorder produced by histamine-releasing autoantibodies in 
about 40% of patients. In contrast to angioedema occurring in 
the context of an allergic reaction or CU, the pathophysiology 
of recurrent idiopathic angioedema without urticaria remains 
unclear. Although bradykinin is known to play a major role 
in the pathophysiology of angioedema caused by hereditary 
or acquired C1-inhibitor deficiency and treatment with 
angiotensin-converting enzyme inhibitors, the mediators 
involved in idiopathic nonhistaminergic angioedema and 
related factors acting as triggers or enhancers of vascular 
permeability remain unclear [2,10,11]. 
The aim of this study was to assess autoreactivity in patients 
with idiopathic recurrent angioedema associated or not with 
urticaria. Autoreactivity was evaluated in vivo using the ASST 
and in vitro by measuring serum-induced basophil histamine 
release (BHR).
 
 
Patients and Methods
The study population comprised 19 patients with recurrent 
idiopathic angioedema without wheals (13 males and 6 
females; median age, 45 [range, 27-78] years), 38 patients 
with angioedema and CU (8 males and 30 females; median 
age, 40.5 [range, 14-76 ] years), and 52 patients with CU 
without angioedema (16 males and 36 females; median age, 
37.5 [range, 18-81] years), all of whom were evaluated at the 
allergy center of Ospedale Maggiore Policlinico in Milano, 
Italy. Twenty healthy individuals (11 males and 9 females; 
median age, 40.5 [range, 26-65] years) were selected as 
controls. CU was diagnosed on the basis of the recurrence of 
spontaneous wheals for more than 6 weeks. Physical urticaria 
and other possible causes of urticaria (ie, food and drug allergy 
and parasitosis) were ruled out after appropriate investigations. 
Only patients with chronic spontaneous urticaria were selected 
for the study, whereas patients with physical urticaria and 
urticaria vasculitis were excluded.
At the fi rst visit, based on patients’ recent history and 
according to the number of wheals and degree of pruritus 
present, disease activity was estimated following the urticaria 
activity score (UAS), as recommended in the recent guidelines 
of the European Academy of Allergy and Clinical Immunology 
[12]. According to the UAS, urticaria was classifi ed as mild 
(score 1), moderate (score 2), or severe (score 3). All patients 
had active urticaria with or without angioedema at the time 
of the study.
Patients with idiopathic angioedema without wheals 
reported a history of recurrent angioedema involving different 
sites and organs (mostly affecting the face [including lips 
and eyelids], hands, feet, and genital area) that was not 
accompanied by urticaria and was not triggered by identifi ed 
external agents including drugs, foods, or hymenoptera venom. 
None of the patients had a family history of angioedema or was 
taking angiotensin-converting enzyme inhibitors. Functional 
C1-inhibitor levels, measured using a commercial reagent kit 
(Immuno), and antigenic C1-inhibitor levels, assayed using 
radial immunodiffusion (Dade Behring), were normal in all 
cases, as were serum levels of the complement fractions C3 
and C4. In all patients, treatment with H1 antihistamines at 
the licensed doses had failed to prevent angioedema episodes.
The intradermal ASST was performed with 0.05 mL 
of fresh autologous serum at least 5 days after stopping 
antihistamine therapy (cetirizine, levocetirizine, loratadine, 
desloratadine, or ebastine in all cases) according to the method 
of Sabroe et al [13], with reading of the wheal-and-fl are 
reaction at 30 minutes. Intradermal injection of saline solution 
(0.9% wt/vol) was performed as a negative control and skin 
prick test with 10 mg/mL of histamine as a positive control. 
Patients showing a red wheal with a diameter at least 1.5 mm 
greater than that of the control saline solution were considered 
positive. At the time of blood sampling, none of the patients 
had associated chronic infl ammatory disorders, hepatitis C, 
or a history of recent acute infectious disease. All participants 
gave their informed consent to undergo ASST and peripheral 
blood collection for in vitro assays.
Basophil Histamine Release Assay
Leukocyte suspensions from healthy blood donors were 
prepared by dextran sedimentation of peripheral venous blood 
anticoagulated with 0.01 M EDTA and mixed with 6% dextran 
in saline solution (Plander 70, Fresenius Kabi Italia) and 30 
mM dextrose (Sigma Chemicals). The cells were allowed to 
settle for 60-90 minutes at room temperature, the leukocyte-
rich plasma was aspirated and centrifuged at 300g for 15 
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minutes at 4°C, and the cell button was washed twice in 
Tyrode buffer (pH, 7.4) containing (mM) 140 NaCl, 5.5 
dextrose, 2.7 KCl, 0.36 NaH2PO4, and 12 NaHCO3. Leukocytes 
(with about 7 × 104 basophils) were resuspended in 100 μL of 
Tyrode buffer with 1.8 mM CaCl2 and 0.5 mM MgCl2 and 
incubated with 100 μL of the serum under examination, making 
a fi nal volume of 200 μL. After incubation for 40 minutes at 
37°C, the reaction was stopped by addition of 800 μL of ice-
cold buffer solution and centrifugation at 1000g for 10 minutes 
at 4°C. The supernatants were then aspirated, mixed with an 
equal volume of 6% HClO4 and centrifuged again at 1000g 
for 10 minutes at 4°C. The histamine concentration in the 
supernatants was measured using an automated fl uorometric 
method [14]. Spontaneous histamine release was evaluated by 
measuring the histamine concentration in the supernatant of 
nonstimulated cells incubated for 40 minutes at 37°C. Total 
histamine content was obtained by adding 100 μL of 6% 
HClO4 to 100 μL of cell suspension. Net histamine release 
was calculated as the percentage of total histamine content 
after subtraction of spontaneous release. A 5% release cutoff 
value was used, as previously described [15]. Sera were 
tested with leukocyte suspensions from a normal donor whose 
basophils were previously shown to release 30% of total 
histamine content on challenge with an optimal dose of goat 
polyclonal antihuman IgE (Sigma Chemicals; 10 μg/mL). In 
order to detect the presence of functionally active anti-FcεRI 
autoantibodies, basophil histamine release was also evaluated 
after stripping membrane-bound IgE with 10 mmol/L of lactic 
acid (pH, 3.9; incubation for 3.5 minutes at room temperature), 
a procedure that allows dissociation of FcεRI-bound IgE 
Table 1. Demographic Characteristics
       Patient Category Number Male/Female P Valuea Median Age
  Ratio  (Range), y 
 
Healthy controls 20 11/9  40.5 (26-65)
Angioedema without urticaria 19 13/6  45 (27-78)
Angioedema with chronic 
   urticaria 38 8/30 .001 40.5 (14–76)
Chronic urticaria without 
   angioedema 52 16/36 .018 37.5 (18–81)
aFisher exact test compared to patients with angioedema without urticaria
found for sex distribution, namely, a predominance of 
males among patients with idiopathic angioedema without 
wheals (68.4%) and a minority of males among patients 
with angioedema and CU (21%, P=.001) and among patients 
with CU without angioedema (30.7%, P=.018) (Table 1). 
The ASST result was negative in all healthy controls and in 
patients with idiopathic nonhistaminergic angioedema without 
urticaria; conversely, it was positive in 29 out of 38 patients 
with angioedema and CU (76.3%) and in 26 out of 52 patients 
with CU without angioedema (50%). ASST positivity was 
signifi cantly associated with CU with or without angioedema 
in comparison to patients with idiopathic angioedema without 
wheals (P<.0001 for both patient groups, relative risk, 3.22 for 
CU with angioedema and 1.76 for CU without angioedema); 
furthermore, percentage positivity was higher in patients 
with CU and angioedema than in patients with CU without 
angioedema (P=.015). BHR was positive in 2 out of 19 patients 
with idiopathic angioedema without wheals (10.5%), in 18 out 
of 38 patients with angioedema and CU (47.3%) (P<.0001 
vs healthy controls, relative risk 2.0; P=.007 vs angioedema 
patients), and in 11 patients out of 52 with CU without 
angioedema (21.1%) (P<.03 vs healthy controls; relative risk, 
1.48) (Table 2). The results of histamine release are reported 
in the Figure and show a signifi cant difference between the 4 
groups (P=.0001). BHR was positive only after stripping of 
basophil membrane-bound IgE with lactic acid in 1 patient with 
angioedema without wheals (out of 2 positive), in 1 patient with 
angioedema and CU (out of 18 positive), and in 3 patients with 
CU without angioedema (out of 11 positive). No correlations 
were found between BHR and CU severity score in patients 
Table 2. Positivity of Autologous Serum Skin Test and Basophil Histamine Release Assay
       Patient Category ASST-Positive,% P Valuea BHR-Positive,% P Valuea 
 
Healthy controls 0/20  0/20 (0) 
Angioedema without urticaria 0/19 (0) NS 2/19 (10.5)  NS
Angioedema with chronic 
   urticaria 29/38 (76.3)         <.001 18/38 (47.3) .0001 
Chronic urticaria without 
   angioedema 26/52 (50) <.001  11/52 (21.1) .03  
Abbreviations: ASST, autologous serum skin test; BHR, basophil histamine release; NS, nonsignifi cant.
aFisher exact test compared with healthy controls.
without damaging basophil 
functional activity [16]. One 
assay per serum was performed 
to detect histamine-releasing 
activity. The histamine release 
assay was carried out using the 
same sera as for ASST.
Statistical Analysis
Results were expressed as 
median and range. Proportions 
were compared using the Fisher 
exact test. Differences between 
patient groups were assessed 
using the Kruskal-Wallis test 
and Dunn test. The correlation 
with the UAS was assessed 
using the Spearman rank test. 
P values <.05 were considered 
signifi cant.
 
Results
No differences were found 
between the 3 patient groups 
for median age, whereas a 
significant difference was 
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Figure. Results of serum-induced basophil histamine release in healthy controls and in patients 
with idiopathic angioedema without urticaria, chronic urticaria without angioedema, and chronic 
urticaria with angioedema. Individual values are reported. Horizontal bars are median values. The 
horizontal dotted line represents the cutoff value.
with CU and angioedema or in patients 
with CU without angioedema.
Discussion
The results of this study indicate 
that patients with idiopathic angioedema 
without wheals do not react to intradermal 
injection of autologous serum and do not 
show signifi cant circulating histamine-
releasing activity, unlike patients with 
angioedema and CU, who often show 
autoreactivity. In fact, CU is associated 
with the presence of circulating 
histamine-releasing factors, as assessed 
by ASST and BHR, independently of 
the coexistence of angioedema. Skin 
reactivity to intradermal injection of 
autologous serum in about 50% of 
patients with CU was described in 1986 
by Grattan et al [7] and considered 
indicative of circulating vasoactive 
factors that could be relevant to the pathogenesis of the disease. 
In subsequent years, histamine-releasing autoantibodies 
targeting the high-affi nity IgE receptor or IgE were identifi ed 
in patients with CU [8,9], and ASST was proposed as a 
screening test for functional autoantibodies in CU patients [13]. 
Nowadays, ASST is considered more a test for autoreactivity 
than a specifi c test for histamine-releasing autoantibodies, as 
it has been shown to have moderate specifi city as a marker 
for functional autoantibodies targeting FcεRI or IgE, but 
a high negative predictive value (92.8%) for patients with 
or without CU [17]. According to the expert panel of the 
European Academy of Allergology and Clinical Immunology, 
a negative ASST result is a useful surrogate marker of the 
absence of circulating histamine-releasing autoantibodies [17]. 
Conversely, BHR has been used as a confi rmatory test showing 
the presence of functionally active histamine-releasing 
autoantibodies [18], since a routine in vitro assay able to detect 
circulating and functionally active anti-FcεRIα and/or anti-
IgE autoantibodies is still lacking. Negative ASST results in 
patients with idiopathic angioedema without wheals enable us 
to rule out the presence of histamine-releasing autoantibodies 
in the vast majority of patients. In fact, we were able to detect 
weak serum histamine-releasing activity just above the cutoff 
value in 2 out of 19 patients with idiopathic angioedema 
without wheals, indicating that small amounts of histamine-
releasing autoantibodies may occasionally be present in 
this group. In one patient, histamine-releasing activity was 
detected using basophils bearing membrane IgE, indicating 
the presence of anti-IgE autoantibodies, whereas in the other 
patient, histamine release was observed only after stripping 
basophil-bound IgE, thus suggesting the presence of anti-FcεRI 
autoantibodies. Consistent with previous observations, patients 
with CU either with or without angioedema showed frequent 
autoreactivity, since ASST was positive in 76.3% and 50% 
of cases, respectively, suggesting the presence of circulating 
vasoactive factors and/or histamine-releasing autoantibodies in 
at least half of the patients [7,17]. It is interesting to note that 
the percentage of positive ASST results was higher in patients 
with CU and angioedema than in patients with CU without 
angioedema, thus confi rming the observation by Nettis et al 
[19], who noted that CU patients with angioedema were more 
frequently ASST-positive than those without angioedema. 
Accordingly, patients with a positive basophil activation test 
result showed a higher prevalence of other autoantibodies and 
more severe urticaria and were more likely to have angioedema 
[20]. However, this has not been a consistent fi nding in other 
studies [21,22]. A signifi cant difference between the 3 patient 
groups was also found for BHR: patients with angioedema 
and CU had the strongest serum histamine-releasing activity. 
Therefore, the overall impression is that autoreactivity is more 
common and stronger in patients with angioedema and CU 
than in patients with CU without angioedema. It is noteworthy 
that the percentage of positive BHR results was lower than 
the percentage of positive ASST results in both CU groups, 
indicating lower sensitivity for the former than for the latter, 
as found in a previous study by our group [15] and confi rmed 
by Platzer et al [23]. This fi nding may be explained, at least in 
part, by the characteristics of the basophils used in the assay, 
such as releasability, density of membrane IgE, and availability 
of free FcεRI receptors; in fact, percentage positivity increases 
if basophils from different donors or human mast cells are 
used [24].
In conclusion, negative ASST findings demonstrate 
the lack of circulating vasoactive factors and histamine-
releasing autoantibodies in most patients with idiopathic 
nonhistaminergic angioedema without wheals, in contrast 
to patients with CU either with or without angioedema. 
Furthermore, the predominance of males among patients with 
idiopathic nonhistaminergic angioedema does not support an 
autoimmune origin for this disorder, whereas the predominance 
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of women among patients with CU is consistent with the 
known predilection of autoimmune disorders in females 
[25]. The different rates of autoreactivity, as assessed by 
ASST and BHR, provide an explanation for the different 
effi cacy of H1 antihistamines. In fact, H1 antihistamines are 
scarcely effective in most patients with idiopathic angioedema 
without wheals, whereas they represent the cornerstone of CU 
treatment. Assessment of autoreactivity by ASST, BHR, or 
both may help to predict the response to H1 antihistamines in 
patients presenting with recurrent angioedema.
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